درباره این اپیزود
This episode we look at a bunch of statements from the FDA and from HHS Secretary Robert F. Kennedy, Jr. And of course there are peptides to talk about these days. Does anyone really know what’s going on with those?
Our deep dive is a special one: Our guest is Al Carter, the CEO of the National Association of Boards of Pharmacy, and he gives us a totally different perspective on the regulatory landscape at the level that affects pharmacists every day.
Links from the podcast:
The latest FDA statement on DTE: https://fllw.me/4sL6zXw
The Coalition for Compounding Excellence’s first audit process guide (compounding records and quality control): https://fllw.me/3Oew1qr
FDA Law Blog on the state of peptide compounding: https://fllw.me/4cpFF2C
National Association of Boards of Pharmacy: https://nabp.pharmacy
Join APC! https://a4pc.org/join
